OGT 918 ( DrugBank: - )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
19	Lysosomal storage disease	2
299	Cystic fibrosis	2

19. Lysosomal storage disease

---

Clinical trials : 854 /  Drugs : 716 - (DrugBank : 105) / Drug target genes : 70 - Drug target pathways : 191

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00316498 (ClinicalTrials.gov)	October 17, 2002	19/4/2006	Saccadic Eye Movements in Patients With Niemann-Pick Type C Disease	A Phase I/II Randomized, Controlled Study of OGT 918 in Adult and Juvenile Patients With Niemann Pick C Disease	Niemann Pick Diseases	Drug: OGT918	National Eye Institute (NEI)	NULL	Completed	12 Years	N/A	All	30	Phase 1	United States;United Kingdom
2	NCT00041535 (ClinicalTrials.gov)	July 5, 2002	9/7/2002	OGT 918-006: A Phase I/II Randomized, Controlled Study of OGT 918 in Patients With Neuronopathic Gaucher Disease	A Phase I/II Randomized, Controlled Study of OGT 918 in Patients With Neuronopathic Gaucher Disease	Gaucher Disease	Drug: OGT 918	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Completed	4 Years	N/A	All	30	Phase 2	United States;United Kingdom

299. Cystic fibrosis

---

Clinical trials : 1,696 /  Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00537602 (ClinicalTrials.gov)	November 2007	28/9/2007	Miglustat / OGT 918 in the Treatment of Cystic Fibrosis	Single Center, Double-blind, Randomized, Placebo-controlled, 2-period/2-treatment Crossover Study Investigating the Effect of Miglustat on the Nasal Potential Difference in Patients With Cystic Fibrosis Homozygous for the ?F508 Mutation	Cystic Fibrosis	Drug: miglustat;Drug: placebo	Actelion	NULL	Terminated	12 Years	N/A	Both	6	Phase 2	Spain
2	EUCTR2006-002049-35-ES (EUCTR)	22/07/2007	28/05/2007	Estudio unicéntrico, a doble ciego, aleatorizado y controlado con placebo, cruzado de 2 brazos, para investigar el efecto de miglustat sobre la diferencia de potencial nasal en pacientes con fibrosis quística homocigotos para la mutación ?F508	Estudio unicéntrico, a doble ciego, aleatorizado y controlado con placebo, cruzado de 2 brazos, para investigar el efecto de miglustat sobre la diferencia de potencial nasal en pacientes con fibrosis quística homocigotos para la mutación ?F508	fibrosis quística MedDRA version: 8.1;Level: LLT;Classification code 10011762;Term: Cystic fibrosis	Trade Name: Zavesca Product Name: miglustat Product Code: OGT 918 INN or Proposed INN: Miglustat Other descriptive name: 1,5 (Butylimino)-1,5-dideoxy-D-glucitol	Actelion Pharmaceuticals Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	25		Spain